Barbara De Servi has obtained a Biology degree at the University of Milan in 1998 and in 2002 the PhD in physiopathology at University of Milan and at DKFZ, in Heidelberg. In 2005-2006, she was post-doctoral fellow at the University of Verona medical school. Since 2007, she is study director at VitroScreen, in charge to develop tailor-made "omics" research models and identify toxicity pathways on 3D human tissue models.
Statement of the Problem: Nasal irrigation with saline solutions is frequently used for relief of rhinitis symptoms. Literature suggests that manganese (Mn) contributes to a decrease in allergic nasal response. In vitro research studies were conducted on 3D model of airway epithelium to evaluate efficacy and safety of a Mn-enriched seawater solution called Stérimar Allergic Nose (SAN). Methodology: The 3D Reconstituted Human Nasal Epithelium model (RHNE) was treated with 10 μL of SAN twice a day for four days to simulate repeated use (full strength) or untreated (control). For epithelium integrity (safety), the control and SAN-treated cultures were analyzed for: Trans-Epithelial-Electrical-Resistance (TEER) on days 1 (D1) and 4 (D4) post-treatment, and release of Lactate Dehydrogenase (LDH) and Interleukin 8 (IL-8) daily from D1 to D4. For efficacy, Mucociliary Clearance (MCC) and stimulation of epithelium-regeneration were assessed. MCC was measured by video-microscopy on D1 and D4 after the same treatment regimen. For epithelium-regeneration, RHNE was treated with 30 μL of SAN or saline. After a glass capillary injury, made 1 hour after treatment, regeneration stimulation was assessed as a percentage of wound closure by comparative photography immediately after the injury and 2, 6, 22 and 30 hours later. Findings: SAN showed an average TEER of 302 and 323 ohm.cm2 (p<0,001) on D1 and D4, respectively, safely above tissue integrity limit (100 ohm.cm2). LDH and IL-8 releases were similar for SAN and control at all-time points, also confirming epithelium integrity and safety. SAN showed a significant MCC increase as compared to control (P<0.01). Furthermore, SAN showed faster and greater wound closure than control (86.59% for SAN versus 50.65% at 22 hours). Conclusion: SAN demonstrated efficacy and safety in the in vitro assays. The results support the use of Mn-enriched SAN in relief of rhinitis symptoms.
Gilbert Glady has completed his MD at the age of 27 years from Strasbourg university of medicine and postdoctoral studies from Besançon and Paris-Nord universities of medicine. He got during all these years an expertise in immunology and immunogenetics and developed also interest for alternative medicines. So he becames at 2010 the creator of the BI(G)MED method and director of EBMA, the European association for training the medical profession at the BI(G)MED. He has participated in numerous international congresses in the field of immuno-allergology, infectiology and oncology with posters and oral presentations.
Inflammatory upper airway diseases, particularly chronic rhinosinusitis (CRS) and allergic rhinitis (AR), have a high worldwide prevalence. CRS and AR involve sustained and exaggerated inflammation that is associated with marked changes in gene and protein expression under tight regulation. MicroRNAs represent one of the fundamental epigenetic regulatory mechanisms used by cells that can mediate posttranscriptional gene silencing of target genes. As fine tuning regulators of gene expression, miRNAs are involved in diverse biologic processes, including cell proliferation, apoptosis, and differentiation, organ development, metabolism, stress responses, and signal transduction. Emerging evidence implicates an involvement of miRNAs in shaping the inflammation pattern in upper airways. Studies regarding the roles of miRNAs in allergic diseases have multiplied during the last 4 years, and the functions of miRNAs in the regulation and pathogenesis of these diseases are more and more better characterized. Recently, miRNAs have been shown to be detectable in cell-free body fluids such as serum and plasma samples. The circulating miRNAs are protected from blood RNAses either by existing in cell membrane-derived vesicles such as exosomes or by forming a complex with lipid-protein carriers such as high-density lipoprotein. So it becomes possible to use such kind of molecules for a therapeutic purpose, and that is what achieve the Bio Immun(G)en Medicine – BI(G)MED – by introducing high diluted microRNAs in nano compounds looking for a fine regulation in different upper airways diseases with an allergic etiology.